I am buying more and holding Gale shares for these good reasons:
(1) All scientific data based on all clinical trials to date confirm that NeuVax is safe, very minimal side effects and can substantially prevent breast cancer from recurring after all standard treatments.
(2) Folate Bind Protein is safe with low side effects and can effectively prevent ovarian cancer.
(3) Pain skilling medication for cancer is around $400 million annually. Abstral is the best in this class. A modest 15% penetration of this market would yield $60 million annual revenue for Gale. Furthermore, Abstral will transform Gale from a purely drug R&D company onto a company with a strong product line which is able to stabilize its financial position.
Buy and hold Gale shares and we will be nicely rewarded!!!